drugset / Trial / NCT07324707

Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

NCT07324707

Phase 2 Recruiting 30 enrolled Anhui Palo Alto Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhaler in patients with bronchial asthma.

Timeline

Start
2025-10-15
Primary completion
2026-03
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 200 ug Inhaled
Subject PA9159 Small molecule 120 ug Inhaled

Indications